Recombinant all-human anti-IL-12/23 monoclonal antibody injection is the world's first clinically similar ursuzumab biosimilar drug. Potential indications include psoriasis, psoriatic arthritis, Crohn Disease, ulcerative colitis, systemic lupus erythematosus, etc. In January 2018, IND application was approved for clinical development. In November of the same year, the first phase clinical trial was initiated. It is expected that the first phase of clinical research will be completed by the end of 2019.